No. of patients | 257 |
Dates of transplant | March 1995-January 2000 |
Mean follow-up (range) (mo) | 12 (1-60) |
Median age (range) (y) | 42 (16-63) |
Diagnosis | |
AML/ALL | 123 (47.8%) |
CML CP1 | 65 (25.3%) |
NHL/CLL | 29 (11.3%) |
MM | 22 (8.6%) |
MDS | 18 (7%) |
Phase of disease | |
Early | 143 (55.6%) |
Advanced | 114 (44.4%) |
Sex | |
F to M | 61 (23.7%) |
M to M | 80 (31.1%) |
F to F | 53 (20.6%) |
M to F | 55 (21.4%) |
Cytomegalovirus serology | |
D and R negative | 29 (11.3%) |
D and/or R positive | 212 (82.5%) |
D or R NA | 16 (6.2%) |
ABO incompatibility | |
Major | 48 (18.7%) |
Myeloablative regimen | |
TBI based | 140 (54.5%) |
Bu based | 117 (45.5%) |
GVHD prophylaxis | |
CsA + PDN or MTX | 169 (65.8%) |
CsA | 82 (31.9%) |
None | 6 (2.3%) |
Cell content of the graft* (mean and range) | |
CD34+ cells | 4 (0.6-15) |
CD3+ cells | 0.3 (0-2.8) |
G-CSF posttransplant | 73 (28.4%) |
Cryopreservation | 72 (28%) |
No. of patients | 257 |
Dates of transplant | March 1995-January 2000 |
Mean follow-up (range) (mo) | 12 (1-60) |
Median age (range) (y) | 42 (16-63) |
Diagnosis | |
AML/ALL | 123 (47.8%) |
CML CP1 | 65 (25.3%) |
NHL/CLL | 29 (11.3%) |
MM | 22 (8.6%) |
MDS | 18 (7%) |
Phase of disease | |
Early | 143 (55.6%) |
Advanced | 114 (44.4%) |
Sex | |
F to M | 61 (23.7%) |
M to M | 80 (31.1%) |
F to F | 53 (20.6%) |
M to F | 55 (21.4%) |
Cytomegalovirus serology | |
D and R negative | 29 (11.3%) |
D and/or R positive | 212 (82.5%) |
D or R NA | 16 (6.2%) |
ABO incompatibility | |
Major | 48 (18.7%) |
Myeloablative regimen | |
TBI based | 140 (54.5%) |
Bu based | 117 (45.5%) |
GVHD prophylaxis | |
CsA + PDN or MTX | 169 (65.8%) |
CsA | 82 (31.9%) |
None | 6 (2.3%) |
Cell content of the graft* (mean and range) | |
CD34+ cells | 4 (0.6-15) |
CD3+ cells | 0.3 (0-2.8) |
G-CSF posttransplant | 73 (28.4%) |
Cryopreservation | 72 (28%) |
AML indicates acute myeloblastic leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia; CP, chronic phase; NHL, non-Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; MM, multiple myeloma; MDS, myelodisplastic syndrome; F, female; M, male; D, donor; R, recipient; NA, not available; TBI, total body irradiation; Bu, busulphan; GVHD, graft-versus-host disease; CsA, cyclosporine A; PDN, prednisone; MTX, methotrexate; G-CSF, granulocyte colony-stimulating factor.
×106/kg.